BjussuMP-II, a venom metalloproteinase, induces the release and cleavage of pro-inflammatory cytokines and disrupts human umbilical vein endothelial cells
Hallison Mota Santana,Yoda Janaina Ikenohuchi,Milena Daniela Souza Silva,Braz Junior Campos Farias,Suzanne Nery Serrath,Carolina Pereira Da Silva,João Gabriel Dos Santos Magalhães,Larissa Faustina Cruz,Daniel Gomes Cardozo,Alex Ferreira E Ferreira,Valdison Pereira Dos Reis,Rafaela Diniz-Sousa,Charles Nunes Boeno,Mauro Valentino Paloschi,Anderson Maciel DE Lima,Andreimar Martins Soares,Sulamita da Silva Setúbal,Juliana Pavan Zuliani,João Gabriel dos Santos Magalhães,Alex Ferreira e Ferreira
DOI: https://doi.org/10.1016/j.cbi.2024.110986
IF: 5.168
2024-04-09
Chemico-Biological Interactions
Abstract:Snake venom metalloproteases (SVMPs) are hydrolytic enzymes dependent on metal binding, primarily zinc (Zn 2+ ), at their catalytic site. They are classified into three classes (P–I to P-III). BjussuMP-II, a P–I SVMP isolated from Bothrops jararacussu snake venom, has a molecular mass of 24 kDa. It exhibits inhibitory activity on platelet aggregation and hydrolyzes fibrinogen. TNF-α upregulates the expression of adhesion molecules on endothelial cell surfaces, promoting leukocyte adhesion and migration during inflammation. Literature indicates that SVMPs may cleave the TNF-α precursor, possibly due to significant homology between metalloproteases from mammalian extracellular matrix and SVMPs. This study aimed to investigate BjussuMP-II's effects on human umbilical vein endothelial cells (HUVEC), focusing on viability, detachment, adhesion, release, and cleavage of TNF-α, IL-1β, IL-6, IL-8, and IL-10. HUVEC were incubated with BjussuMP-II (1.5–50 μg/mL) for 3–24 h. Viability was determined using LDH release, MTT metabolization, and 7AAD for membrane integrity. Adhesion and detachment were assessed by incubating cells with BjussuMP-II and staining with Giemsa. Cytokines were quantified in HUVEC supernatants using EIA. TNF-α cleavage was evaluated using supernatants from PMA-stimulated cells or recombinant TNF-α. Results demonstrated BjussuMP-II's proteolytic activity on casein. It was not toxic to HUVEC at any concentration or duration studied but interfered with adhesion and promoted detachment. PMA induced TNF-α release by HUVEC, but this effect was not observed with BjussuMP-II, which cleaved TNF-α. Additionally, BjussuMP-II cleaved IL-1β, IL-6, and IL-10. These findings suggest that the zinc metalloprotease BjussuMP-II could be a valuable biotechnological tool for treating inflammatory disorders involving cytokine deregulation.
pharmacology & pharmacy,biochemistry & molecular biology,toxicology